Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDS
Previous Symbol
CUSIPN/A
Phone408-385-1742
Debt
Debt-to-Equity RatioN/A
Current Ratio5.04
Quick Ratio5.04
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees30
Outstanding Shares8,100,000
Market Cap$77.81 million
OptionableNot Optionable
Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions
What is Aridis Pharmaceuticals' stock symbol?
Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."
How were Aridis Pharmaceuticals' earnings last quarter?
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) released its earnings results on Tuesday, November, 13th. The company reported ($1.97) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.92. The company had revenue of $1.02 million for the quarter, compared to analysts' expectations of $0.33 million. View Aridis Pharmaceuticals' Earnings History.
When is Aridis Pharmaceuticals' next earnings date?
What price target have analysts set for ARDS?
5 brokerages have issued twelve-month price targets for Aridis Pharmaceuticals' stock. Their predictions range from $23.00 to $40.00. On average, they anticipate Aridis Pharmaceuticals' stock price to reach $28.25 in the next twelve months. This suggests a possible upside of 194.3% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.
What is the consensus analysts' recommendation for Aridis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.
What are Wall Street analysts saying about Aridis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aridis Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Aridis announced that the first subject has been enrolled in its P1/2a study evaluating AR-501 for the treatment of chronic bacterial lung infections in patients with cystic fibrosis (CF)." (12/12/2018)
- 2. According to Zacks Investment Research, "Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. " (11/20/2018)
- 3. Cantor Fitzgerald analysts commented, ". After a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month price target of $25 for ARDS shares. We continue to believe that upward earnings revisions and multiple expansion will drive the stock higher. We think a greater appreciation for the company’s pipeline drugs will increase earnings estimates to levels not yet reflected in consensus expectations." (11/13/2018)
Has Aridis Pharmaceuticals been receiving favorable news coverage?
News headlines about ARDS stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of Aridis Pharmaceuticals' key competitors?
Some companies that are related to Aridis Pharmaceuticals include Marker Therapeutics (MRKR), Minerva Neurosciences (NERV), Aclaris Therapeutics (ACRS), Aratana Therapeutics (PETX), Verastem (VSTM), Avid Bioservices (CDMO), Merus (MRUS), Albireo Pharma (ALBO), Kadmon (KDMN), Athersys (ATHX), BIOFRONTERA AG/ADR (BFRA), MannKind (MNKD), Intec Pharma (NTEC), Syros Pharmaceuticals (SYRS) and Savara (SVRA).
Who are Aridis Pharmaceuticals' key executives?
Aridis Pharmaceuticals' management team includes the folowing people:
- Vu L. Truong, CEO, Director & Chief Scientific Officer
- Fred Kurland, CFO & Principal Accounting Officer
- Wolfgang Dummer, Chief Medical Officer
- Steven M. Chamow, Vice President-Research & Development
- Lisa Sher, Head-Investor & Public Relations
When did Aridis Pharmaceuticals IPO?
(ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.
When does the company's lock-up period expire?
Aridis Pharmaceuticals' lock-up period expires on Monday, February 11th. Aridis Pharmaceuticals had issued 2,000,000 shares in its public offering on August 14th. The total size of the offering was $26,000,000 based on an initial share price of $13.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
How do I buy shares of Aridis Pharmaceuticals?
Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aridis Pharmaceuticals' stock price today?
One share of ARDS stock can currently be purchased for approximately $9.60.
How big of a company is Aridis Pharmaceuticals?
Aridis Pharmaceuticals has a market capitalization of $77.81 million. Aridis Pharmaceuticals employs 30 workers across the globe.
What is Aridis Pharmaceuticals' official website?
How can I contact Aridis Pharmaceuticals?
Aridis Pharmaceuticals' mailing address is 5941 OPTICAL COURT, SAN JOSE CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]
MarketBeat Community Rating for Aridis Pharmaceuticals (NASDAQ ARDS)
MarketBeat's community ratings are surveys of what our community members think about Aridis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
